Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2010 - 2026)
Jazz Pharmaceuticals (JAZZ) posted quarterly Other Non-Current Assets of $7.1 million for Q1 2026, down 21.1% year-over-year from $9.0 million in Q1 2025, and down 92.83% quarter-over-quarter from $99.0 million in Q4 2025.
Jazz Pharmaceuticals (JAZZ) Other Non-Current Assets (2010 - 2026) Analysis & Trends
Jazz Pharmaceuticals' Other Non-Current Assets history runs 17 years deep, the most recent figure standing at $7.1 million for Q1 2026.
- In Q1 2026, Other Non-Current Assets fell 21.1% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (down 21.1% YoY), while the FY2025 annual figure was $99.0 million, up 943.31% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $7.1 million, down from $99.0 million in the prior quarter.
- The five-year high for Other Non-Current Assets was $99.0 million in Q4 2025, with the low at $4.4 million in Q3 2024.
- The 5-year median for Other Non-Current Assets is $8.6 million (2023), against an average of $20.0 million.
- The sharpest annual moves came in 2023 and 2025: Other Non-Current Assets slumped 88.25% in 2023, then surged 943.31% in 2025.
- Jazz Pharmaceuticals' Other Non-Current Assets stood at $55.1 million in 2022, then plunged by 88.25% to $6.5 million in 2023, then surged by 46.48% to $9.5 million in 2024, then soared by 943.31% to $99.0 million in 2025, then sank by 92.83% to $7.1 million in 2026.
- Business Quant data shows JAZZ's Other Non-Current Assets at $7.1 million in Q1 2026, $99.0 million in Q4 2025, and $8.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 124.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 42.45 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 109.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 18,237.65 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 62.96 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 65.13 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 104.44 Mn |
| 10 | Jazz Pharmaceuticals | 15.90 Bn | 14.28 Bn | 1.09 Bn | 86.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 86.30 Mn |
| Mar 31, 2026 | 7.10 Mn |
| Dec 31, 2025 | 99.00 Mn |
| Sep 30, 2025 | 8.03 Mn |
| Jun 30, 2025 | 8.52 Mn |
| Mar 31, 2025 | 9.00 Mn |
| Dec 31, 2024 | 9.49 Mn |
| Sep 30, 2024 | 4.40 Mn |
| Jun 30, 2024 | 71.43 Mn |
| Mar 31, 2024 | 5.78 Mn |
| Dec 31, 2023 | 6.48 Mn |
| Sep 30, 2023 | 7.17 Mn |
| Jun 30, 2023 | 7.87 Mn |
| Mar 31, 2023 | 8.56 Mn |
| Dec 31, 2022 | 55.14 Mn |
| Sep 30, 2022 | 9.95 Mn |
| Jun 30, 2022 | 10.64 Mn |
| Mar 31, 2022 | 11.34 Mn |
| Dec 31, 2021 | 40.81 Mn |
| Sep 30, 2021 | 12.72 Mn |